

Han Soo Yoo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1363451/publications.pdf>

Version: 2024-02-01

89

papers

1,348

citations

331670

21

h-index

501196

28

g-index

92

all docs

92

docs citations

92

times ranked

1666

citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 51, 43-48.	2.2	79
2	Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α -synuclein chaperone. <i>Brain</i> , 2019, 142, 2845-2859.	7.6	44
3	Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil. <i>Cancer</i> , 1991, 68, 1878-1884.	4.1	43
4	Olfactory dysfunction in Alzheimer's disease and Lewy body-related cognitive impairment. <i>Alzheimer's and Dementia</i> , 2018, 14, 1243-1252.	0.8	42
5	Frontal atrophy as a marker for dementia conversion in Parkinson's disease with mild cognitive impairment. <i>Human Brain Mapping</i> , 2019, 40, 3784-3794.	3.6	41
6	A Nomogram for Predicting Amyloid PET Positivity in Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 681-691.	2.6	38
7	Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease. <i>Nutrition</i> , 2021, 83, 111090.	2.4	36
8	Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 10531.	3.3	35
9	Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnosed Parkinson Disease. <i>Neurology</i> , 2021, 96, e2121-e2131.	1.1	32
10	Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: preliminary findings. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, S54-S58.	2.3	31
11	Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease. <i>Brain</i> , 2021, 144, 1127-1137.	7.6	30
12	Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. <i>Neurology</i> , 2019, 92, e2015-e2026.	1.1	28
13	Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 33, S128-S133.	2.3	27
14	White matter hyperintensities as a predictor of freezing of gait in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 105-109.	2.2	27
15	Dopaminergic Depletion, β -Amyloid Burden, and Cognition in Lewy Body Disease. <i>Annals of Neurology</i> , 2020, 87, 739-750.	5.3	27
16	Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinson's Disease: Impact on Clinical Features. <i>Journal of Movement Disorders</i> , 2019, 12, 113-119.	1.3	26
17	Amyloid- β -related and unrelated cortical thinning in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2018, 72, 32-39.	3.1	25
18	Clinical relevance of amnesic versus non-amnesic mild cognitive impairment subtyping in Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 766-773.	3.3	25

#	ARTICLE	IF	CITATIONS
19	Patterns of striatal dopamine depletion in early Parkinson disease. <i>Neurology</i> , 2020, 95, e280-e290.	1.1	25
20	Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 423-431.	6.4	24
21	Patterns of olfactory functional networks in Parkinson's disease dementia and Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2020, 89, 63-70.	3.1	24
22	Repeated Thrombolytic Therapy in Patients with Recurrent Acute Ischemic Stroke. <i>Journal of Stroke</i> , 2013, 15, 182.	3.2	24
23	The Influence of Body Mass Index at Diagnosis on Cognitive Decline in Parkinson's Disease. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
37	Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD. <i>Neurology</i> , 2019, 92, e1468-e1478.	1.1	16
38	White matter hyperintensities and risk of levodopa-induced dyskinesia in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 229-238.	3.7	16
39	Sleep Disturbance May Alter White Matter and Resting State Functional Connectivities in Parkinson's Disease. <i>Sleep</i> , 2017, 40, .	1.1	15
40	Cerebellar connectivity in Parkinson's disease with levodopa-induced dyskinesia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2251-2260.	3.7	15
41	Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns. <i>Neurobiology of Aging</i> , 2020, 87, 11-17.	3.1	15
42	Initial motor reserve and long-term prognosis in Parkinson's disease. <i>Neurobiology of Aging</i> , 2020, 92, 1-6.	3.1	15
43	Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 169-174.	1.9	14
44	Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1652-1660.	6.4	11
45	A Novel Heterozygous <i>ANO3</i> Mutation with Basal Ganglia Dysfunction in a Patient with		

#	ARTICLE	IF	CITATIONS
55	Interrelation of striatal dopamine, brain metabolism and cognition in dementia with Lewy bodies. <i>Brain</i> , 2022, 145, 4448-4458.	7.6	9
56	Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 4203-4212.	3.6	8
57	Gender-specific effect of urate on white matter integrity in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 41-47.	2.2	7
58	Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson's disease. <i>Scientific Reports</i> , 2020, 10, 5567.	3.3	7
59	Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. <i>Scientific Reports</i> , 2021, 11, 14394.	3.3	7
60	Minimal parkinsonism in the elderly is associated with striatal dopamine loss and pontine structural damage. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 140-143.	2.2	6
61	Inosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA) Trial. <i>Journal of Parkinson's Disease</i> , 2021, 11, 0.784314.	4.7	6
62	Impaired functional connectivity of sensorimotor network predicts recovery in drug-induced parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 16-21.	2.2	5
63	Interaction of CSF α -synuclein and amyloid beta in cognition and cortical atrophy. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12177.	2.4	5
64	Temporalis Muscle Thickness as an Indicator of Sarcopenia Is Associated With Long-term Motor Outcomes in Parkinson's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 2242-2248.	3.6	5
65	Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy. <i>Stem Cells International</i> , 2021, 2021, 1-10.	2.5	5
66	A Case of Isolated Middle Cerebral Artery Stenosis with Hemichorea and Moyamoya Pattern Collateralization. <i>Journal of Movement Disorders</i> , 2013, 6, 13-16.	1.3	5
67	Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson's disease. <i>European Journal of Neurology</i> , 2020, 27, 1948-1956.	3.3	5
68	Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?. <i>CNS Drugs</i> , 2018, 32, 971-979.	5.9	4
69	Neural Correlates of Cognitive Performance in Alzheimer's Disease- and Lewy Bodies-Related Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 873-885.	2.6	4
70	Urate is closely linked to white matter integrity in multiple system atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1029-1039.	3.7	4
71	Structural connectivity networks in Alzheimer's disease and Lewy body disease. <i>Brain and Behavior</i> , 2021, 11, e02112.	2.2	4
72	Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1541-1549.	2.8	4

#	ARTICLE	IF	CITATIONS
73	Neural correlates of self-awareness of cognitive deficits in non-demented patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2021, 28, 4022-4030.	3.3	3
74	Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 129-136.	2.8	3
75	White matter connectivity networks predict levodopa-induced dyskinesia in Parkinson's disease. <i>Journal of Neurology</i> , 2022, 269, 2948-2960.	3.6	3
76	Nodular hepatocellular carcinoma: treatment with intraarterial injection of I-131 Lipiodol. <i>Journal of Korean Medical Science</i> , 1990, 5, 75.	2.5	2
77	A computerized red glass test for quantifying diplopia. <i>BMC Ophthalmology</i> , 2017, 17, 71.	1.4	2
78	The pattern of FP-CIT PET in pure white matter hyperintensities-related vascular parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 1-6.	2.2	2
79	Microstructural Connectivity is More Related to Cognition than Conventional MRI in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 239-249.	2.8	2
80	Effect of Alzheimer's Disease and Lewy Body Disease on Metabolic Changes. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1471-1487.	2.6	2
81	Different patterns of β -amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism. <i>Neurobiology of Aging</i> , 2021, 101, 199-206.	3.1	2
82	[P4492]: OLFACTORY DYSFUNCTION IN ALZHEIMER'S AND LEWY BODY-RELATED COGNITIVE IMPAIRMENT: DIAGNOSTIC IMPLICATION AND ASSOCIATION WITH COGNITION AND BRAIN ATROPHY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1524.	0.8	1
83	Gastrectomy and nigrostriatal dopaminergic depletion in de novo Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 299-301.	3.9	1
84	Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1-11.	2.8	1
85	Diffusion tensor imaging-based pontine damage as a degeneration marker in synucleinopathy. <i>Journal of Neuroscience Research</i> , 2021, 99, 2922-2931.	2.9	1
86	P393: A NOMOGRAM FOR PREDICTING AMYLOID PET POSITIVITY IN AMNESTIC MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1248.	0.8	0
87	O1305: DISTINCT PATTERN OF CORTICAL ATROPHY IN ALZHEIMER'S DISEASE AND LEWY BODY-RELATED COGNITIVE IMPAIRMENT ACROSS THE DISEASE SPAN. <i>Alzheimer's and Dementia</i> , 2018, 14, P254.	0.8	0
88	Effects of APOE4 on Alzheimer's disease, Lewy body disease, cerebral amyloid deposition and cognitive dysfunction. <i>Alzheimer's and Dementia</i> , 2020, 16, e037300.	0.8	0
89	Reply: ARSA gene variants and Parkinson's disease. <i>Brain</i> , 2020, 143, e48-e48.	7.6	0